Deviations in execution from the prescribed drug intake schedules (timing non adherence) are frequent and may pose a substantial risk for therapeutic failure. Simple methods to monitor timing adherence with multiple drugs are missing. A new technology, i.e., the polymedication electronic monitoring system (POEMS) attached to a multidrug punch card, was used in a clinical trial on outpatients with prescribed medicines for vascular risk reduction. The complete delineation of timing adherence allows for the calculation of objective adherence parameters and the linking of exposure with drug-drug interactions. A sub-analysis was performed on 68 patients, who were prescribed lipid lowering therapy. A smaller intake time variability of the lipid lowering drug was significantly associated with better levels of LDL-cholesterol, independently of the time of day. This finding may challenge current general recommendations for the timing of lipid lowering drugs’ intake and substantiate that inter-individual differences in timing adherence may contribute to response variability. Thus, objective parameters based on multidrug adherence monitoring should be considered as independent variables in personalized medicine. In clinical practice, personalized intake recommendations according to patients’ pattern of timing adherence may help to optimize the effectiveness of lipid lowering agents.
References
[1]
DiMatteo, M. Variations in patients’ adherence to medical recommendations: A quantitative review of 50 years of research. Med. Care 2004, 42, 200–209, doi:10.1097/01.mlr.0000114908.90348.f9.
[2]
World Health Organization. Adherence to long-term therapies—Evidence for action; WHO Library Cataloguing-in-Publication Data: Geneva, Switzerland, 2003; pp. 1–194.
[3]
Osterberg, L.; Blaschke, T. Adherence to Medication. N. Engl. J. Med. 2005, 353, 487–497, doi:10.1056/NEJMra050100.
[4]
Cramer, J.A.; Mattson, R.H.; Prevey, M.; Scheyer, R.D.; Ouellette, V.L. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989, 261, 3272–3277.
[5]
Vrijens, B.; Vincze, G.; Kristanto, P.; Urquhart, J. Burnier, M. Adherence to prescribed antihypertensive drug treatments: Longitudinal study of electronically compiled dosing histories. Br. Med J. 2008, 336, 1114–1117.
[6]
Bangsberg, D.; Hecht, F.; Charlebois, E.; Zolopa, A.; Holodniy, M.; Sheiner, L.; Bamberger, J.; Chesney, M.; Moss, A. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000, 14, 357–366.
[7]
Milgrom, H.; Bender, B.; Ackerson, L.; Bowrya, P.; Smith, B.; Rand, C. Noncompliance and treatment failure in children with asthma. J. Allergy Clin. Immun. 1996, 98, 1051–1057, doi:10.1016/S0091-6749(96)80190-4.
[8]
Arnet, I.; Hersberger, K. Polymedication Electronic Monitoring System (POEMS)—Introducing a new technology as gold standard for compliance measurement. J. Patient Compliance 2012, 2, 48–49.
[9]
Urquhart, J.; de Klerk, E. Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens. Stat. Med. 1998, 17, 251–267, doi:10.1002/(SICI)1097-0258(19980215)17:3<251::AID-SIM762>3.0.CO;2-A.
[10]
Vrijens, B.; Goetghebeur, E. Comparing compliance patterns between randomized treatments. Control. Clin. Trials. 1997, 18, 187–203, doi:10.1016/S0197-2456(96)00235-8.
[11]
Goue Gohore, D.; Fenneteau, F.; Barrière, O.; Li, J.; Nekka, F. Rational drug delineation: A global sensitivity approach based on therapeutic tolerability to deviations in execution. Pharmacol. Pharm. 2010, 1, 42–52.
[12]
Pearson, T.; Laurora, I.; Chu, H.; Kafonek, S. The lipid treatment assessment project (l-tap): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch. Intern. Med. 2000, 160, 459–467.
[13]
Walter, P.; Arnet, I.; Hersberger, K. Fundamental progress in investigating drug resistance with Electronic Multidrug Compliance Monitoring (e-MCM). J. Patient Compliance 2011, 1, 42–47.
[14]
Horne, R.; Weinman, J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J. Psychosom. Res. 1999, 47, 555–567, doi:10.1016/S0022-3999(99)00057-4.
[15]
Morisky, D.E.; Ang, A.; Krousel-Wood, M.; Ward, H.J. Predictive validity of a medication adherence measure in an outpatient setting. J. Clin. Hypertens. (Greenwich) 2008, 10, 348–354.
[16]
Karow, T.; Lang-Roth, R. Allgemeine und Spezielle Pharmakologie; Elsevier: Pulheim, Germany, 2012.
[17]
Burnier, M.; Schneider, M.P.; Chiolero, A.; Stubi, C.L.F.; Brunner, H.R. Electronic compliance monitoring in resistant hypertension: The basis for rational therapeutic decisions. J. Hypertens. 2001, 19, 335–341, doi:10.1097/00004872-200102000-00022.
[18]
Plakogiannis, R.; Cohen, H. Optimal low-density lipoprotein cholesterol lowering—Morning versus evening statin administration. Ann. Pharmacother. 2007, 41, 106–110.
[19]
Chapman, R.; Benner, J.; Petrilla, A.; Tierce, J.; Collins, S.; Battleman, D.; Schwartz, J. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch. Intern. Med. 2005, 165, 1147–1152.
[20]
Osterberg, L.G.; Urquhart, J.; Blaschke, T.F. Understanding forgiveness: Minding and mining the gaps between pharmacokinetics and therapeutics. Clin. Pharmacol. Ther. 2010, 88, 457–459, doi:10.1038/clpt.2010.171.
[21]
Delgado-Rodriguez, M.; Llorca, J. Bias. J. Epidemiol. Community Health 2004, 58, 635–641, doi:10.1136/jech.2003.008466.
